Investor''s Presentation

Analyst Day Multiyear TargetsMgmt Guided Margin ImprovementCfo Debt Reduction RoadmapOrder Pipeline DisclosedInvestor Communications View source PDF

3BBLACKBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-10.3%1-day move

₹1249.00

prior close

₹1172.10

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-1.1-1.0-0.2-0.2-10.3-8.0-9.6-9.9-7.5-0.6-3.5-3.9——

Up moveDown movePending

AI summary

3B BlackBio Dx Ltd (formerly Kilpest India Ltd) reported strong FY 2025-26 consolidated revenue of ₹14,191.81 Lakhs, up 47% from ₹9,646.86 Lakhs in FY 2024-25. The company's Molecular Diagnostics (MDx) division drove growth with sales reaching ₹13,111.81 Lakhs, including contributions from newly acquired Coris BioConcept SRL, Belgium (₹3,591.19 Lakhs). Consolidated PAT grew 26% to ₹5,992.98 Lakhs, with EPS improving to ₹69.94 from ₹55.66. The company operates in 70+ countries with 1,000+ customers and expects 15-20% growth in MDx for FY 2026-27. Challenges noted include geopolitical tensions affecting Bangladesh exports (22% de-growth) and Middle East markets, plus Chinese competition impacting Coris' infectious disease segment.

Likely market impact

Strong profit growth and international expansion signal business momentum, though geopolitical headwinds in key export markets and increasing competition may create near-term volatility. The Coris acquisition adds diversification but also brings exposure to Belgian government contract concentration.